BIMERVAX emulsion for injection COVID-19 Vaccine (recombinant, adjuvanted) clinical trials

Open-label, Multi-centre, Non-Inferiority study of safety and immunogenicity of BIMERVAX as heterologous booster for the prevention of coronavirus disease 2019 (COVID-19) in adolescents from 12 years to less than 18 years of age.

This study is looking at a new COVID-19 booster vaccine called BIMERVAX for teenagers aged 12 to 17. It aims to see if BIMERVAX is as safe and effective as another vaccine, HIPRA-HH-2, in boosting protection against the Omicron variant of COVID-19.